Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Etropal ADXBUL:ETR -1.50%50 10-Year ROIIC % is 8.23 as of Dec. 2025. GuruFocus rates XBUL:ETR with a GF Score™ of 50/100 and a GF Value™ of €8.81 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 691 Medical Devices & Instruments companies, Etropal AD ranks better than 62.66% on this metric.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Etropal AD's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.23%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Etropal AD's 10-Year ROIIC % or its related term are showing as below:
XBUL:ETR's 10-Year ROIIC % is ranked better than 62.66% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 2.31
vs XBUL:ETR: 8.23
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Etropal AD 10-Year ROIIC % Related Terms
Etropal AD 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Etropal AD's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XBUL:ETR vs ISRG, BDX, RMD: 10-Year ROIIC % Comparison
For the Medical Instruments & Supplies subindustry, Etropal AD's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Etropal AD 10-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Etropal AD's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Etropal AD's 10-Year ROIIC % falls into.
Etropal AD's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( 0.4426641 (Dec. 2025) - 0.0795314 (Dec. 2015) )
/
( 9.948 (Dec. 2025) - 5.536 (Dec. 2015) )
=
0.3631327
/
4.412
=
8.23%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Etropal AD (XBUL:ETR) has a 10-Year ROIIC % of 8.23 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Etropal AD and its competitors. According to the industry distribution chart, Etropal AD ranks #258 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 37.3%.
Is Etropal AD's 10-Year ROIIC % too high?
Etropal AD's current 10-Year ROIIC % is 8.23. The Medical Devices & Instruments industry median 10-Year ROIIC % is 2.31. Etropal AD's value of 8.23 is 256.3% above this industry median. Based on the distribution chart, Etropal AD ranks #258 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Etropal AD has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Etropal AD's 10-Year ROIIC % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Etropal AD ranks #258 out of 691 companies for 10-Year ROIIC %. This puts Etropal AD in the upper half of its industry. The industry median 10-Year ROIIC % is 2.31. Etropal AD's value of 8.23 is 256.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Medical Devices & Instruments company?
The median 10-Year ROIIC % among Medical Devices & Instruments companies is 2.31, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Etropal AD's current 10-Year ROIIC % of 8.23 is 256.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Etropal AD and its competitors. For the Medical Devices & Instruments industry, the median 10-Year ROIIC % is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Etropal AD's current 10-Year ROIIC % is 8.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Etropal AD stock overvalued right now?
Based on GuruFocus' analysis, Etropal AD (XBUL:ETR) is currently considered Significantly Undervalued. The stock's GF Value™ is €8.81, compared to a current price of €2.62 — trading 70.3% below its estimated fair value. The current 10-Year ROIIC % is 8.23 and 256.3% above the Medical Devices & Instruments industry median of 2.31. Etropal AD's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Etropal AD (XBUL:ETR), the current 10-Year ROIIC % is 8.23 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Etropal AD (XBUL:ETR) Overvalued in 2026?
Based on GuruFocus' analysis, Etropal AD stock appears to be undervalued.
The current stock price of €2.62 is trading 70.3% below its estimated GF Value™ of €8.81.
GuruFocus considers Etropal AD to be Significantly Undervalued.
Key valuation signals for XBUL:ETR:
10-Year ROIIC %: 8.23
GF Value™: €8.81 vs. price of €2.62 (70.3% below fair value)
Industry Position: 256.3% above the Medical Devices & Instruments median (#258 of 691)
No single metric tells the full story. See the XBUL:ETR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.
50GF Score
Get the complete analysis for XBUL:ETR
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XBUL:ETR has been successfully added to your 
